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SPARC is expressed in renal interstitial fibrosis and in renal vascular
injury. Tubulointerstitial inflammation and fibrosis are critical determi-
nants for renal function and prognosis in a variety of human nephropa-
thies. Yet, the pathophysiology of the injury remains obscure. We
investigated the expression of SPARC (secreted protein acidic and rich in
cysteine) by immunohistochemistry and in situ hybridization in experimen-
tal models characterized by tubulointerstitial fibrosis and matrix expansion
in rats. SPARC is a secreted glycoprotein that has been demonstrated to
affect cellular interaction with matrix proteins, modulate cell proliferation,
bind to and/or inhibit growth factors such as PDGF and bFGF, and
regulate angiogenesis. Interstitial expression of SPARC was most promi-
nent in passive Heyman nephritis (PHN), chronic cyclosporine A (CsA)
nephropathy, and the remnant kidney model and, to a lesser extent, in
angiotensin II (Ang 11)-infused animals. SPARC protein and mRNA were
substantially increased at sites of tubulointerstitial fibrosis/matrix expan-
sion. In the PHN model, SPARC protein was expressed by interstitial
fibroblasts that also produced a-smooth muscle actin ("myofibroblasts")
and correlated both temporally (r = 0.97) and spatially with sites of type
I collagen deposition. Interstitial cell proliferation preceded the develop-
ment of interstitial fibrosis, and maximal SPARC expression (d15) coin-
cided with the initial decline in interstitial proliferation. In the Ang
Il-infusion model, which is characterized by arteriolopathy and tubuloin-
terstitial injury, an increase in SPARC protein and mRNA was also seen
in injured blood vessels. SPARC was shown to be expressed by vascular
smooth muscle cells and also by cells in the adventitia of hypertrophied
arteries. In summary, SPARC was transiently expressed by interstitial
fibroblasts at sites of tubulointerstitial injury and fibrosis, and by smooth
muscle cells and cells in the adventitia of injured arteries in the Ang
Il-model. In addition to its proposed role in extracellular matrix deposi-
tion, the antiproliferative properties of SPARC might contribute to the
resolution of interstitial fibroblast proliferation in the PHN model.
Tubulointerstitial inflammation and fibrosis are typical of vir-
tually all progressive renal diseases and are characterized by an
alteration of the normal tubulointerstitial architecture due to the
accumulation of extracellular matrix proteins within the intersti-
tial space. Numerous studies have demonstrated that the extent of
chronic tubulointerstitial damage has been the best histologic
correlate of the decline in renal function and the best predictor of
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long-term renal outcome in a broad variety of renal diseases
including mesangial proliferative glomerulonephritis and focal
segmental glomerulosclerosis [1, 2], lupus nephritis [3, 4], mem-
branous nephropathy [2, 5] and chronic interstitial nephritis of all
types [6, 7].
In this study we investigated the role of SPARC in the
development of interstitial fibrosis in a variety of models of renal
disease that are characterized by interstitial fibrosis. SPARC
(secreted protein acidic and rich in cysteine), also known as
osteonectin and BM-40, is an extracellular matrix-associated
glycoprotein, synthesized by a variety of cells and expressed at
sites of tissue remodeling [8, 9]. SPARC has been shown to bind
to collagen types I, III, IV, V and VIII and has been implicated in
extracellular matrix deposition [81. In addition to affecting cell
shape [10], SPARC has been shown to inhibit proliferation of
various cell types, including endothelial cells, fibroblasts, and
smooth muscle cells [11—14]. Specifically, in aortic endothelial
cells, the cell cycle was arrested in the mid-Gi phase [14]. SPARC
also binds to the B-chain of PDGF (platelet-derived growth
factor), a mitogen that stimulates the proliferation of vascular
smooth muscle cells, fibroblasts, and mesangial cells [15, 16]. In
addition, SPARC was shown to augment the production of
plasminogen activator inhibitor-i (PAl-i) and was associated with
a decrease in the synthesis of fibronectin [17, 181. SPARC can
induce the expression of metalloproteases such as the 92 kDa
gelatinase, stromelysin, and collagenase in synovial fibroblasts
indicating a potential role in the regulation of extracellular matrix
turnover [19]. SPARC expression has been shown to be increased
by a variety of cytokines and growth factors, including transform-
ing growth factor (TGF)-/31, IL-i, CSF-i, progesterone, and
glucocorticoids [81.
This study demonstrates that SPARC is expressed by interstitial
n-smooth muscle actin-positive fibroblasts ("myofibroblasts") in
the tubulointerstitium, and that it colocalizes with cells expressing
type I collagen in experimental models in which interstitial fibrosis
occurs. When individual animals were compared, a close correla-
tion (r = 0.97) could be shown between SPARC and collagen type
I expression in the first 15 days of the PHN model, an experimen-
tal model of membranous nephopathy. Interstitial expression of
SPARC correlated with the resolution of interstitial cell prolifer-
ation at day 15 of the PHN model. We also show that SPARC was
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expressed by vascular smooth muscle cells and adventitial cells in
injured arteries of angiotensin II (Ang 11)-infused animals.
Methods
Experimental protocols
Passive Heyman nephritis (PHN), an experimental model of
membranous nephropathy [20], was induced in male Sprague-
Dawley rats (190 to 210 grams body wt; Tyler Laboratories,
Bellevue, WA, USA) by a single i,v. injection of a sheep anti-Fx1A
antibody (N = 6). The antibody was prepared as described
elsewhere [211. Controls included six Sprague-Dawley rats in-
jected with sterile 0.9% NaC1 solution and six rats injected with
anti-Fx1A but depleted of complement with cobra venom factor
(CVF; Diamedix, Miami, FL, USA) before disease induction [22].
Twenty-four-hour urinary protein excretion was determined in all
rats before sacrifice to assure significant disease. Rats were
sacrificed at days 5, 10, 15, 21 and 30, and renal biopsies were
obtained.
Experimental cyclosporine (CsA) nephropathy was induced in
male Sprague-Dawley rats (N = 8; Charles River, Wilmington,
MA, USA) weighing 225 to 250 grams [231. Rats were housed in
individual cages in a temperature- and light-controlled environ-
ment. All rats received a low salt diet (0.05% sodium, Tekiad,
Madison, WI, USA). CsA, provided by Sandoz Research Institute
(East Hanover, NJ, USA), was diluted in olive oil to a final
concentration of 15 mg/ml. Rats were treated with CsA 15 mg/kg
s.c. (C5A, N = 8) or vehicle olive oil 1 mi/kg s.c. (VH, N = 8) for
35 days.
Remnant kidney model. We studied male Sprague-Dawley rats
(Simonsen, Gilroy, CA, USA) weighing 140 to 160 grams at the
start of the experiment [24]. In the remnant kidney group (N =8),
a right subcapsular nephrectomy and infarction of approximately
two-thirds of the left kidney was accomplished by ligation of the
posterior and 1 or 2 anterior extrarenal branches of the main renal
artery. In the control group (N = 8), we performed a sham
operation consisting of laparotomy and manipulation of the renal
pedicles but without destruction of renal tissue. Rats in each
group underwent renal biopsy by flank incision under ether
anesthesia at four weeks and were subsequently killed by an
overdose of sodium pentobarbital.
Angiotensin II infusion model. Male Sprague-Dawley rats (400
to 500 g; N = 6; Zivic Miller, Allison Park, PA, USA) received
Angiotensin II infusion (200 ng/min dissolved in Ringer's lactate;
Sigma Chemical Co., St. Louis, MO, USA) continuously by
subcutaneous osmotic minipumps (Alzet model 2002, Alza Corp.,
Palo Alto, CA, USA) [25]. Control rats (N = 6) received Ringer's
lactate by minipump. Rats in each group underwent renal biopsy
by flank incision under ether anesthesia at 7 and 14 days and were
subsequently killed by an overdose of sodium pentobarbital.
Renal morphology and immunohistochemistiy
Renal biopsies were fixed in methyl Carnoy's solution (60%
methanol, 30% chloroform, 10% acetic acid) and were embedded
in paraffin [26]. Four-micron sections were stained with periodic
acid and Schiff's reagent (PAS) and were counterstained with
hematoxylin. Indirect immunoperoxidase staining and immuno-
fluorescence were performed on 4 jim sections as described
previously [27—29], with the following primary antibodies: A
murine monoclonal antibody (AON-5031) directed against hu-
man, rat, and bovine SPARC/osteonectin (Haematologic Tech-
nologies Inc., Essex Jet., VT, USA) [30, 31]; a murine monoclonal
1gM antibody against the proliferating cell nuclear antigen
(PCNA) (19A2; Coulter Immunology, Hialeah, FL, USA) [32]; a
murine monoclonal IgG2 antibody against a-smooth muscle actin
(Sigma Chemical Co.) [32]; ED-I, a monoclonal antibody used as
a marker for macrophages/monocytes and dendritic cells [32], and
a polyclonal guinea pig antibody directed against rat collagen I [9].
SPARC and type I collagen expression by interstitial cells was
graded by calculation of the percentage of tubules surrounded by
SPARC or collagen I-positive interstitial cells per field (0.25 mm2)
at a x200 magnification with an ocular grid. At least 12 fields
measuring 0.25 mm2 were counted. For each time point, biopsies
of at least six different animals were assessed in a blinded fashion.
Interstitial cell proliferation was assessed by determination of
the number of interstitial PCNA-positive cells per 0,0625 mm2 at
a x400 magnification. At least 12 fields, each measuring 0.0625
mm2, were counted. Interstitial cells were defined as cells that
were located in between tubules and did not consist of arterial,
arteriolar, or glomerular cells.
Interstitial fibrosis was scored semiquantitatively by a blinded
observer, who examined cortical tubulointerstitial fields on Mas-
son's Trichrome-stained renal biopsies with the x20 objective. A
minimum of 30 fields was assessed in each biopsy. The following
semiquantitative score was used: score 0 = normal interstitium
and tubules; score 1 = mild fibrosis with minimal interstitial
thickening between the tubules; score 2 = moderate fibrosis with
moderate interstitial thickening between the tubules; score 3 =
severe fibrosis with severe interstitial thickening between the
tubules.
Immunohistochemical double labeling. Double immunolabeling
for SPARC and a-smooth muscle actin was performed to deter-
mine the cell types expressing SPARC in our disease models.
Tissue was fixed with Methyl-Carnoy's solution, embedded in
paraffin, and stained by an indirect immunofluorescence tech-
nique for SPARC and for a-smooth muscle actin, a marker for
myofibroblasts [32] and vascular smooth muscle cells [33]. Tissue
sections were first incubated with a murine monoclonal IgGI
antibody directed against SPARC (AON-5031) (Haematologic
Technologies Inc.) overnight at 4°C, followed sequentially by a 60
minute incubation with a biotinylated rabbit anti-mouse IgGi
antibody (Zymed, San Francisco, CA, USA) at room temperature
(RT), a 60 minute incubation with a biotinylated goat anti-rabbit
antibody (Vector) at RT, and a 60 minute incubation with Texas
Red-labeled Avidin D (Vector) at RT in the dark. The next step
consisted of an overnight incubation with a murine monoclonal
IgG2a antibody directed against a-smooth muscle actin (Sigma),
followed by a 60 minute incubation with an FITC (fluorescein
isothiocyanate)-labeled anti-mouse IgG2a antibody (Cappel,
West Chester, PA, USA). Cross reactivity between the FITC-
conjugated anti-mouse IgG2a antibody used to detect a-smooth
muscle actin and the IgGi (SPARC antibody) was ruled out by
omission the a-smooth muscle actin antibody. FITC staining was
riot observed under these circumstances.
Double immunolabeling for SPARC and type I collagen was
performed to determine whether collagen I was expressed by the
same cells that produce SPARC and whether the two proteins
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Fig. 1. SPARC protein is expressed in areas of tubulointerstitial fibrosis. In normal rats (A), SPARC was expressed by visceral glomerular epithelial cells
(arrows) in the glomeruli but was absent from the tubulointerstitium. SPARC was increased in glomerular epithelial cells and in interstitial fibroblasts
in passive Heyman nephritis (PHN) (B) at day 10. In experimental CsA (cyclosporine) nephropathy (C), SPARC was expressed by interstitial cells
around dilated and atrophic tubules at day 35. In the remnant kidney model (D) (4weeks), SPARC was also expressed in the tubulointerstitium, in large
part by interstitial fibroblasts. In the angiotensin Il-infusion model (day 14) (E), SPARC was also present in the tubulointerstitium.
were colocalized. For SPARC, the same staining protocol as in the
SPARC/a-smooth muscle actin double labeling was used. After
these steps were completed, tissue sections were treated with an
Avidin-Biotin blocking kit (Vector). The next step consisted of an
overnight incubation with a guinea-pig anti-type I collagen anti-
body at 4°C, followed by a 60 minute incubation with a biotinyl-
ated goat anti-guinea-pig antibody (Vector) subsequently de-
tected by FITC-conjugated streptavidin D (Vector).
Double immunolabeling for SPARC and ED-I positive macro-
phages was performed to determine whether SPARC was ex-
pressed by ED-I-positive macrophages in the adventitia of injured
blood vessels. The same staining protocol described above in the
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Table 1. Interstitial expression of SPARC" and type 1 collagent', interstitial cell proliferation", and interstitial fibrosis scored in animals with
experimental membranous nephropathy (PHN model)
Normal control
PHN
day 5
PHN
day 10
PHN
day 15
PHN
day 21
PHN
day 30
SPARC express %"
Collagen expression %t
Interstitial cell proliferation"
0
0
6.4 0.64
0.7 0.2
0.7 0.1"
51.2 9.6°
53.3 2.2°
46.6 2.0"
168 49.6°
62.5 4.4°
61.2 2.3"
65.6 8
23.1 6.6°
45.7 4.8"
33.6 4.8
6.9 3.8
35.1 7.0"
11.2 1.6
Interstitial fibrosis score (0_3)' 0 0 0.5 0.1 0.6 0.2 2.1 0.4° 2.3 0.6°
For an explanation of scoring, see Methods section. Values are expressed as mean SE
"Percent of tubules surrounded by cells staining for SPARC
b Percent of tubules surrounded by cells staining for type I collagen
C Number of PCNA-positive interstitial cells per mm2
d Described in Methods section
"P < 0.005 vs. control
fp < 0.05 vs. control.
Fig. 2. SPARC mRNA is expressed by interstitial cells in areas of tubulointerstitial injury, in normal control rats the levels of SPARC were low, as illustrated
by the presence of very few grains [black in the brightfield (A) and white in the darkfield (B)]. In contrast, in a PHN animal at day 10, an increase in
the number of grains could be observed in interstitial areas [black in the brightfield (C) and white in the darkfield (D)]. In C, the high power inset (X400)
shows that grains primarily localized to interstitial cells (large arrow), and not to tubular epithelial cells (small arrows) or the tubular lumen (L).
SPARC/a-smooth muscle actin double labeling was used to detect minutes at room temperature as a blocking step, followed by
SPARC. After completion of these steps, tissue sections were incubation with the ED-I antibody for 60 minutes at room
incubated with goat anti-mouse Fabi fragments (Vector) for 45 temperature. The last step consisted of an incubation with an
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Fig. 3. SPARC is expressed by n-smooth muscle actin positive "myofibro-
blasts." Immunohistochemistry for SPARC (red) revealed that SPARC
was expressed by interstitial cells (A). a-Smooth muscle actin expression
(green) showed a similar distribution on the same tissue section (B). In
contrast to SPARC, however, a-smooth muscle actin also strongly stained each primary antibody with an irrelevant antibody of the same
a smooth muscle cell in a small artery (arrow). The double exposure species or omission of each secondary or tertiary antibody. Under
revealed that the majority of SPARC-positive cells also stained for no circumstances did controls exhibit staining.
a-smooth muscle actin (orange, C). The vascular smooth muscle cell was
labeled only with the antibody directed against a-smooth muscle actin and
therefore appears green (C), whereas very few cells in the interstitium In situ hybridization for SPARC mRNA(possibly macrophages) contained SPARC alone (arrows) (PHN, day 10).
SPARC mRNA was detected by in situ hybridization on forma-
FITC-conjugated donkey anti-mouse-IgG antibody (Jackson Im- un-fixed tissue according to a modification of the method of Reed
munoResearch Laboratories, Inc., West Grove, PA, USA). Con- et a! [91, Pichler et al [34] and Holland et a! [35]. Riboprobes were
trols for the double-immunostaining included replacement of transcribed with an RNA transcription kit (Promega; Madison,
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Fig. 5. Interstitial SPARC expression colocalizes and correlates with inter-
stitial type I collagen deposition. When immunohistochemistry for SPARC
was performed on a Section of a PHN animal at day 10 (A, opposite page),
positive staining was observed in interstitial areas (red). Staining for type
I collagen on the same tissue section (B, opposite page) showed a similar
distribution (green). The double exposure (C, opposite page) revealed
that the majority of interstitial cells expressed both SPARC and type I
collagen (orange). However, type I collagen seemed to predominate in the
extracellular space and exhibited a reticular staining pattern. When
quantification was performed for interstitial SPARC and type I collagen
staining in the PHN model, the time course of both molecules was similar
through day 15 (D, above). Comparison of individual animals (day 0 until
day 15) revealed a close correlation (r = 0.97). After day 15, however,
expression of SPARC decreased more rapidly than that of type I collagen.
Symbols are: () interstitial SPARC; (•) interstitial collagen I.
WI, USA) in the presence of s4355J-dUTP (Amersham, Arling-
ton Heights, IL, USA). The specific activity of the probe was
approximately 3 to 4 X iO cpm/itg. The SPARC riboprobe was
transcribed from a 1147 bp BamHI/HindIII mouse eDNA frag-
ment, cloned in an antisense orientation relative to the SP6
promoter in a pGEM-1 vector. Before use the SPARC riboprobe
was reduced to less than 150 bp fragments by alkaline hydrolysis.
Sections were mounted overnight on Probe-On slides (Fisher,
Pittsburgh, PA, USA), hydrated with a graded series of ethanol,
rinsed in PBS, post-fixed with 4% PFA for 20 minutes, rinsed in
PBS, and digested for 2 to 3 minutes with proteinase K (2.5 xg/ml
in 50 mrvt Tris-HC1 with 5 mt EDTA) (BRL, Gaithersburg, MD,
USA). Samples were rinsed with PBS, fixed with 4% PFA for five
minutes, dipped in Water treated with diethylpyrocabonate
(DEPC-water), exposed to 0.1 M triethanolamine (pH 8) with
0.05% (vol/vol) acetic anhydride for 10 minutes, rinsed in PBS for
five minutes, dipped in DEPC-watcr, dehydrated in graded solu-
tions of ethanol (70 to 100%), and air-dried. Sections were treated
ovenight at 50°C in prehybridization solution 0.6 M NaCI, 0.12 M
Tris-HC1 (pH 81, 8 ms EDTA, 0.02% Ficoll 400, 0.02% polyvi-
nylpyrrolidone, 0.1% Pentex BSA (Sigma), 500 xg/ml salmon
sperm DNA, 600 jxg/ml yeast total RNA, and 50% deionized
formamide]. The samples were hybridized at 50°C overnight in
prehybridization solution that contained 10% dextran sulfate and
0.1 xg/ml of the SPARC anti-sense and sense riboprobes. Samples
were washed for 30 minutes at 50°C in formamide buffer (50%
Fig. 4. Type I collagen expression is increased in areas of tubulointerstitial
fibrosis. When immunohistochemistiy for type I collagen was performed
on kidney sections of normal control animals (A), only faint staining could
be observed in interstitial areas. In an animal with interstitial matrix
expansion, however (PHN, day 10), a significant increase in type I collagen
staining was observed (B).
formamide, 5% 20 X SSC [1 x SSC is 0.15 M NaC1, 0.015 M
Na-citate, pH 7.5, 1% 1 M DTT (dithiotreitol) in DEPC-water],
for 30 minutes at room temperature in 0.5 X SSC, and for 30
minutes at 37°C in 3.5 X SSC with 40 .tg/ml RNAse A (Sigma)
and 50 p1 RNAse Ti (Sigma). Slides were incublated sequentially
in 3.5 X SSC for 10 minutes at room temperature and 0.1 X SSC
for 90 minutes at 65°C. Sections were dehydrated with ethanol
(solutions of 50, 70, 95, and 100%) containing 0.3 M sodium
acetate and were subsequently air-dried. We performed autora-
diogaphy with NTB 3 emulsion (Kodak, Rochester, NY, USA)
diluted to 40% with a solution of 4% Dreft detergent; slides
exposed for 5 to 7 days at 4°C were developed in Kodak D-i9
developer and fixed in GBX fixer (Kodak). Samples were coun-
terstained with toluidine blue, dehydrated with ethanol (solutions
of 70 to 100%), cleared in xylene, and mounted with Permount.
Statistical analysis
Statistical significance was defined as P < 0.05 and was evalu-
ated by ANOVA (analysis of variance) followed by the Fisher's
PLSD (protected least significant difference) procedure. Statisti-
cal values are expressed as mean SCM.
D
o 80
(I)
a
60
'a
C
::
80
0
60
40
20 a
a
0
0 10 20 30 40
Time, days
a.'
1984 Pichler et al: SPARC in interstitial fibrosis and arteriolopathy
Fig. 6. Proliferation of interstitial a-smooth muscle actin positive "myofibro-
blasts" in the PHN model precedes interstitial fibrosis. We performed double
immunolabeling for PCNA and a-smooth muscle actin in the PHN model
to identif' the proliferating interstitial cells. This technique revealed that
the majority of interstitial PCNA-positive cells was a-smooth muscle
actin-positive (A). PCNA (nuclear staining; small arrow) is shown in dark
gray, and SPARC (cytoplasmic staining; large arrow) is shown in brown.
Several PCNA-positive cells are also present in the tubular lumen. B. The
proliferative response clearly preceded the development of interstitial
fibrosis. Symbols are: (LI) interstitial PCNA; (+) interstitial fibrosis.
Maximal interstitial SPARC-expression levels correlate with the resolu-
tion of interstitial cell proliferation. C. The relationship between intersti-
tial SPARC expression and interstitial cell proliferation. Maximal expres-
sion levels of SPARC coincide with the initial decline in interstitial cell
proliferation. Symbols are: (LI) interstitial PCNA; (•) interstitial
SPARC.
Fig. 8. Vascular smooth muscle cells are a major source of SPARC in
injured blood vessels of angiotensin II-injhsed animals. Double immunola-
beling for SPARC and a-smooth muscle actin was performed to deter-
mine the cell type that expressed SPARC. Immunohistochemistry for
SPARC (red) showed expression in the media and adventitia of the blood
vessel (A). Immunostaining for a-smooth muscle actin (green) on the
same tissue section outlined the vascular smooth muscle cells (B). The
double exposure demonstrated that vascular smooth muscle cells are a
major source of SPARC (orange; C), however, SPARC was also expressed
by cells in the adventitia.
Results
SPARC protein and mRNA are expressed by interstitial cells in areas
of tubulointerstitial fibrosis in experimental models of renal disease
We performed immunohistochemistry for SPARC in several
models of renal disease which are characterized by the develop-
ment of interstitial fibrosis. In normal rats SPARC was primarily
expressed by visceral glomerular epithelial cells but was absent
from the interstitium (Fig. IA). In passive Heymann nephritis
(PHN), an experimental model of membranous nephropathy,
SPARC was not only expressed in increased amounts by glomer-
ular epithelial cells, as reported previously [36], but was also
expressed by spindle-shaped interstitial cells in areas of extracel-
lular matrix expansion (Fig. IB). In the PHN model, interstitial
SPARC expression was minimally elevated at day 5, when only
0.6% of the tubules were surrounded by interstitial cells staining
for SPARC. SPARC expression was significantly elevated at day
10 (53.3%), was maximal at day 15 (62.5%), and decreased
thereafter (Table 1). Complement depletion with CVF prevented
the development of disease, and no increase in SPARC expression
was observed.
In all other models that we studied, SPARC was also increased
in the interstitium in association with interstitial fibrosis. In
experimental cyclosporine A (CsA) nephropathy, SPARC was
expressed by interstitial cells in areas of interstitial fibrosis at day
35. Staining for SPARC was particularly prominent around di-
lated and atrophic tubules (Fig. 1C). In the remnant kidney
model, SPARC was expressed by interstitial cells in areas of
fibrosis/matrix expansion (Fig. 1D). In the angiotensin II (Ang
11)-infusion model, SPARC was also expressed by spindle-shaped
interstitial cells in areas of interstitial fibrosis (Fig. IE), as well as
in injured blood vessels (see below).
When in situ hybridization for SPARC on tissue sections of
normal control animals was performed, only low levels of SPARC
mRNA could be detected in the tubulointerstitium (Fig. 2A). A
significant increase in interstitial SPARC mRNA, however, could
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however, such as in the PHN model, a substantial increase in
interstitial collagen I was observed by immunohistochemical
staining (Fig. 4B). Similar to SPARC, the type I collagen was
localized largely to spindle-shaped interstitial cells. In the PHN
model, expression of type I collagen was only minimally elevated
at day 5, when 0.6% of the tubules were surrounded by interstitial
cells staining for this collagen. The percentage of tubules sur-
rounded by type I collagen-positive cells was substantially in-
creased at day 10 (46.6%), reached maximal levels at day 15
(61.2%), and decreased thereafter to 35.1% on day 30 (Ta-
ble 1).
Interstitial SPARC expression colocalizes and correlates with
interstitial collagen type I deposition in the PHN model
Since immunohistochemistry for type I collagen showed a
highly similar distribution compared to SPARC in areas of
tubulointerstitial injuiy/fibrosis, we performed double-immunola-
beling for SPARC and type I collagen in the PHN model to
determine whether they were in fact colocalized. The majority of
SPARC-expressing cells also expressed type I collagen (Fig.
5A-C). Whereas immunohistochemistry for SPARC was limited
to the cells (cytoplasm and cell surface), immunostaining for
collagen type I also included extracellular reticular fibers (Fig.
5C).
When the timecourse of interstitial SPARC expression was
50 compared with that of interstitial type I collagen in the PHN
model, a significant correlation (r = 0.97) for the expression of
both molecules could be shown for the time between the induction
of the disease (day 0) and day 15 of the PHN model. Expression
2 of both SPARC and of type I collagen reached maximal levels atday 15 in the PHN model, when 62.5 and 61.2% of the tubules
were surrounded by SPARC or type I collagen-positive interstitial
cells, respectively (Table 1; Fig. 5D). Thereafter, interstitial
SPARC decreased more rapidly than interstitial type I collagen
Interstitial proliferation of a-smooth muscle actin positive cells
precedes the development of interstitial fibrosis in the PHN model
Interstitial cell proliferation was assessed in the PHN model by
the counting of PCNA (proliferating cell nuclear antigen, a
marker for cell proliferation)-positive interstitial cells. A mild
increase in proliferation (P = 0.83, not statistically significant) was
noted at dayS, with 51.2 PCNA positive cells per mm2 versus 6.4
proliferating cells in the control animals (Table 1). Interstitial cell
proliferation reached maximal levels at day 10 with 168 PCNA
positive cells per mm2 (P < 0.0001) and started to resolve at day
15 with 65.6 PCNA positive cells per mm2 (P < 0.04). At days 21
and 30, no statistically significant increase in PCNA-positive cells
could be observed (Table 1).
To identify the PCNA-positive interstitial cells, we performed
double immunolabeling for PCNA and a-smooth muscle actin.
This technique revealed that the majority of interstitial prolifer-
ating cells (> 75%) stained for a-smooth muscle actin (Fig. 6A).
Interstitial cell proliferation preceded the development of
interstitial fibrosis. At day 5, no fibrosis was detected despite
modest interstitial cell proliferation. (Fig. 6B). Proliferation had
also subsided by day 21, despite a progressive increase in fibrosis,
which was maximal at day 30 (Fig. 6B and Table 1).
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Fig. 6 (continued)
be observed in areas of interstitial fibrosis for all the disease
models, including the PHN model (Fig. 2B).
Interstitial cells expressing SPARC are a-smooth muscle actin-
positive (myofibroblasts)
To identify the cell type expressing SPARC in the interstitium,
we performed double-immunolabeling for SPARC and a-smooth
muscle actin, since the latter is expressed by activated interstitial
fibroblasts (myofibroblasts) [321. This technique revealed that the
majority (> 90%) of interstitial cells expressing SPARC also
expressed a-smooth muscle aetin and therefore corresponded to
"myofibroblasts" (Fig. 3).
Collagen type I is also expressed in interstitial areas of
tubulointerstitial fibrosis
In normal rats type I collagen was expressed at low levels by
some interstitial cells (Fig. 4A), presumably fibroblasts [371,
around collecting ducts, in the media and adventitia of blood
vessels, and in the renal capsule. In rats with interstitial fibrosis,
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Interstitial SPARC expression correlates with the resolution of
interstitial cell proliferation in the PHN model
Interstitial cell proliferation in passive Heyman nephritis was
maximal at day 10. By day 15 a rapid and substantial decrease in
proliferating cells of more than 60% was observed. The initial
decline of interstitial cell proliferation coincided with the maximal
levels of SPARC on day 15 (Fig. 6C).
SPARC protein and mRNA are expressed in injured blood vessels
of angiotensin Il-infused rats
In angiotensin Il-infused rats, focal areas of fibrinoid necrosis
involving the afferent arteriole and other small arteries were
observed by light microscopy (PAS stain) by day 7. A striking
finding was that SPARC protein was substantially increased in the
areas of vascular injury (Fig. 7B), in comparison to SPARC
expression in blood vessels of vehicle-infused animals (Fig. 7A).
Within the blood vessels, high levels of SPARC protein were
noted in the media, adventitia, and endothelium (Fig. 7B). Since
macrophages are a potential source of SPARC [8] and since
macrophages have been found in the adventitia of injured blood
vessels in this model [321, immunohistochemistry for ED-i-
positive macrophages was performed on serial sections (Fig. 7C).
Macroph ages were located primarily at the periphery of the blood
vessel. Only 10 to 20% of these macrophages were also positive
for SPARC by double immunolabeling (data not shown).
In situ hybridization for SPARC in control animals showed only
low levels of SPARC mRNA (Fig. 7 D, E). In contrast, angioten-
sin TI-infused animals demonstrated a substantial increase of
SPARC mRNA in injured blood vessels (Fig. 7 F, G), a result
consistent with the immunohistochemical data shown in Figure
7B.
SPARC is expressed by vascular smooth muscle cells and by cells
in the adventitia of injured blood vessels in angiotensin II
infused rats
To identify the cells expressing SPARC in angiotensin II-
mediated vascular injury, we performed double-immunolabeling
for SPARC and a-smooth muscle actin. Whereas immunostaining
for SPARC primarily labeled the smooth muscle cells in the
media of the artery (Fig. 8A), weak staining for SPARC was also
observed in the media, adventitia, and endothelium. The double
exposure (Fig. 8C) revealed that more than 50% of the cells that
expressed SPARC were vascular smooth muscle cells in the tunica
media; the remainder appeared to be distibuted among cells in the
adventitia and intima.
Discussion
In this study we have examined the expression of SPARC in
interstitial fibrosis and in injured blood vessels in experimental
models of renal disease. SPARC was consistently expressed by
interstitial cells in areas of interstitial fibrosis in experimental
models of membranous nephropathy (PHN model), CsA ne-
phropathy (CsA model), focal segmental glomerulosclerosis (rem-
nant kidney model), and hypertensive renal disease (Ang II-
model). In the PHN model, SPARC was expressed by interstitial
"myofibroblasts" in areas of interstitial fibrosis, in which the
degree of expression and the time course correlated closely with
that of type I collagen (r = 0.97). Maximal interstitial SPARC in
this model correlated with the resolution of interstitial cell
proliferation. SPARC expression was also found to be substan-
Fig. 7. SPARC protein and mRNA are increased in injured blood vessels of
angiotensin Il-infused animals. When immunohistochemistry for SPARC
was performed on a normal blood vessel, only faint staining could be
observed (A). A substantial increase in vascular SPARC was observed at
day 7 in the angiotensin 11-infusion model (B). Immunohistochemistry for
ED-i-positive macrophages on a serial section showed that macrophages
localized primarily to the periphery of the blood vessel (C). In Situ
hybridization for SPARC on a section of a vehicle-infused animal dem-
onstrated low expression levels of SPARC mRNA in a blood vessel black
grains in brightfield D); white grains in darkfield (E)I. In injured blood
vessels of angiotensin Il-infused rats, however, a substantial increase in
SPARC mRNA was observed [black grains in brightfield (F); white grains
in darkfield (G)].
tially increased in vascular smooth muscle cells and in adventitial
cells of proliferating, injured blood vessels of angiotensin-Il
infused rats.
Our studies provide the first documentation that SPARC is
ItJ-
, •
•!
•: ••a
St. 'W
- ._-_t -.
-
p
I -
..ø*7
'-21:)
,'•--'..
S
a
' 4 4
4
•
-
. S • 4
•• —: -.
—
-.
-4' t'• ., S.
-I,
- 0
-
-4 •I2
-e. -
•. •4l'
•.a,_s •_. s4,lb I;•b S
a -
#4f W-
• •.iLt .
--
.12*(
. -':.t -*;,
- •--Q.-t-, - -
. r. ,.-
?
!' .1; '7 •
•
•'11
• '1.
I
14
Pichier ci a!: SPARC in interstitial fibrosis and arteriolopathy 1987
Fig. 7. Continued.
expressed by interstitial fibroblasts during renal interstitial fibro-
genesis. Progressive fibrogenesis can be divided into three differ-
ent stages: initiation of fibrogenesis, fibrotic matrix deposition,
and attenuation of fibrogenesis [38]. The initiation process in-
volves cytokines and growth factors such as transforming growth
factor-p (TGF-p), interleukin-1 (IL-i), PDGF, tumor necrosis
factor- a (TNF-a) and y-interferon that stimulate motility, growth
and/or proliferation of fibroblasts [38].TGF-13 and IL-i have also
been shown to be positive regulators of SPARC expression [8].
More fibroblasts are attracted into the tubulointerstitial space by
chemotactic factors including cleavage products of fibroncctin and
type I collagen [39, 40]. Movement of fibroblasts through the
extracellular matrix is facilitated by the secretion of metallopro-
teinases, which compromise the integrity the extracellular matrix
[41]. The second stage is characterized by the deposition of
extracellular matrix. After fibroblasts acquire a synthetic pheno-
type, increase in number, and migrate to areas of active inflam-
mation, they begin to deposit extracellular matrix. The third and
last stage consists of either alleviation or attenuation of inflam-
mation, reduction in synthesis of fibrotic matrix, and stimulation
of proteolysis of fibrotic matrix.
We were able to demonstrate that SPARC is expressed by
interstitial fibroblasts in areas of tubulointerstitial injury, where it
could be involved in several stages of tubulointerstitial fibrogen-
esis. First, SPARC could function in the deposition of extracellu-
lar matrix. We showed that SPARC colocalized and correlated
with interstitial type I collagen, a finding not entirely restricted to
the tubulointerstitium. Our group has previously shown that both
SPARC and collagen type I are also expressed by glomerular
epithelial cells in the experimental model of membranous ne-
phropathy [27, 36] and that SPARC and collagen type I are also
expressed by mesangial cells in experimental mesangial prolifer-
ative glomerulonephritis [34, 42]. In both instances, overexpres-
sion of SPARC was associated with increased extracellular matrix
deposition. Since SPARC has been shown to bind to collagen type
I, it is conceivable that SPARC could act as a nucleation site for
type I and other interstitial collagen fibrils in tubulointerstitial
fibrosis, similar to its proposed role in bone [43] or in hepatic
fibrosis [44]. The fact that immunohistochemistry for SPARC was
primarily restricted to the fibroblasts themselves (and not to the
extracellular matrix), despite the fact that SPARC is a secreted
protein, could result from an antigen-masking effect of the
interstitial collagen fibers bound to extracellular SPARC. In the
PHN model, staining for SPARC declined faster than that for type
I collagen (Table I and Fig. 5D). This observation could also be
due to the shorter half-life of extracellular SPARC.
Second, SPARC could be involved in the regulation of inter-
stitial fibroblast proliferation. Gilbert et al [45] have demonstrated
that a reduction of renal cortical SPARC expression was associ-
ated with an increase in early diabetes-related kidney growth. Our
group has previously shown that SPARC might be a potential
inhibitor of mesangial cell proliferation in glomerulonephritis
[34]. In this study we have demonstrated and confirmed previous
reports from other groups that interstitial fibroblasts proliferate in
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areas of tubulointerstitial injury/fibrosis. One of the growth fac-
tors involved in interstitial fibroblast proliferation appears to be
PDGF. PDGF has been shown to be synthesized by macrophages,
which have been invariably identified in human acute and chronic
interstitial injury [46, 47], and also by tubular epithelial cells.
Interstitial fibroblasts have also been shown to express PDGF
receptors [48]. Recently, Tang et a! have shown that infusion of
PDGF into rats induces proliferation of interstitial fibroblasts
[49]. PDGF mRNA is also expressed at sites of interstitial cell
proliferation and fibrosis in the hypertensive injury induced by
angiotensin II [32]. SPARC has been shown to bind to PDGF
B-chain and thereby inhibit the interaction with its receptor [50].
SPARC has also been shown to inhibit proliferation indepen-
dently of PDGF through the arrest of aortic endothelial cells,
which lack PDGF receptors, in the mid-Gi phase of the cell cycle
[141. Since the maximum of interstitial SPARC expression corre-
lated with the initial decline in interstitial cell proliferation,
SPARC could be involved in the regulation of interstitial fibro-
blast proliferation [111.
Third, SPARC could also play a role in the regulation of
fibroblast migration. SPARC has been shown to induce the
expression of three different metalloproteinases in synovial fibro-
blasts [19], some of which also have been shown to be expressed
by renal fibroblasts [51]. Therefore, SPARC could contribute to
the generation of collagen cleavage products, which are chemo-
tactic for fibroblasts [40], and also to the proteolysis of the normal
extracellular matrix, to facilitate fibroblast migration [41]. Kuhn
and Mason have suggested that SPARC, due to its anti-adhesive
properties, could enhance fibroblast migration in the development
of pulmonary fibrosis [52]. Furthermore, by inhibiting the binding
of PDGF to its receptor, SPARC might interfere with the
chemotactic activity of PDGF for fibroblasts [50, 53].
In the angiotensin II infusion model, SPARC was induced in
blood vessels with morphological changes consistent with fibrinoid
necrosis and vascular hypertrophy. Expression of SPARC was
primarily restricted to vascular smooth muscle cells and cells in
the adventitia. Many studies have demonstrated that the principal
effect of angiotensin IT-mediated hypertension on the peripheral
vasculature involves both a hypertrophic and proliferative re-
sponse [25, 54]. Studies in vitro [55] and in vivo [54] indicate that
this hypertrophic response might be distinct from the effects of
angiotensin II on hypertension and that the hypertrophic response
could involve the increased production of the contractile protein,
a-smooth muscle actin [55]. Our group has also previously shown
that angiotensin Il-mediated hypertension can also induce vascu-
lar smooth muscle cell proliferation in vivo [25, 32]. A component
of the proliferative response to angiotensin II might occur inde-
pendently of hypertension. Angiotensin II, for example, induces
vascular smooth muscle cells to express PDGF [56]. Since SPARC
binds to and inhibits the action of the PDGF dimers AB and BB,
it could function in the regulation of PDGF-mediated smooth
muscle cell proliferation.
In summary, we have shown that SPARC is expressed by
interstitial, a-smooth muscle actin-positive fibroblasts in several
models of renal disease in which interstitial fibrosis occurs, and
that SPARC colocalizes and correlates temporally and spatially
with interstitial type I collagen in the PHN model. Maximal levels
of SPARC in the interstitium correlated with the initial resolution
of interstitial cell proliferation in this model. SPARC is also
expressed in injured blood vessels in rats with Ang IT-mediated
hypertension. These studies indicate a role for SPARC in the
pathogenesis of tubulointerstitial injury. Specifically, SPARC
might modulate the proliferation of interstitial fibroblasts or
vascular smooth muscle cells and/or the deposition of type I
collagen fibers.
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